Proximity-Based Therapeutics: Targeted Protein Degradation and Other Pharmacological Approaches
Feb 16–19, 2025 | Eldorado Hotel & Spa, Santa Fe, NM, United States
Scientific Organizers:
Philip Chamberlain and Fleur M. Ferguson
In Person
On Demand
×
-
Feb 16–19, 2025 | Eldorado Hotel & Spa, Santa Fe, NM, United States
Scientific Organizers: Philip Chamberlain and Fleur M. Ferguson
Philip Chamberlain
Fleur M. Ferguson
Available Formats:
Supported by:
In Person
On Demand
***Meeting program subject to change.
Available Formats: = In Person = On DemandSunday, February 16, 2025
Fundraising
Booking Function
Merchandise Options
Registration Options
Registration
4:00–8:00 PM
Concourse
Welcome Mixer
6:00–8:00 PM
Cava Santa Fe
Monday, February 17, 2025
Breakfast
7:00–8:00 AM
Anasazi Ballroom
Poster Setup
7:30–8:00 AM
Anasazi Ballroom
Poster Viewing
7:45–7:00 PM
Anasazi Ballroom
Welcome and Keynote Address
8:00–9:00 AM
Eldorado Ballroom
* Philip Chamberlain, Neomorph, Inc.
Session Chair
Session Chair
Benjamin F. Cravatt III, The Scripps Research Institute
Activity-Based Proteomics – Protein and Ligand Discovery on A Global Scale
Activity-Based Proteomics – Protein and Ligand Discovery on A Global Scale
Molecular and Structural Biology of Induced Proximity Drugs
9:00–11:15 AM
Eldorado Ballroom
Brenda A Schulman, Max Planck Institute of Biochemistry
E3-Ligase Activation, Regulation and Structure
E3-Ligase Activation, Regulation and Structure
Georg Petzold, Monte Rosa Therapeutics
Mining the CRBN Target Space Redefines Rules for Molecular Glue-induced Neosubstrate Recognition
Mining the CRBN Target Space Redefines Rules for Molecular Glue-induced Neosubstrate Recognition
Hlib Razumkov, Stanford University
Short Talk: Discovery of CRBN-Dependent WEE1 Molecular Glue Degraders From A Multicomponent Combinatorial Library
Short Talk: Discovery of CRBN-Dependent WEE1 Molecular Glue Degraders From A Multicomponent Combinatorial Library
Björn Schwalb, NEOsphere Biotechnologies GmbH
Short Talk: Unbiased Mapping of Cereblon Neosubstrate Landscape by High-Throughput Proteomics
Short Talk: Unbiased Mapping of Cereblon Neosubstrate Landscape by High-Throughput Proteomics
* Jin Wang, Baylor College of Medicine
Expanding Cereblon Neosubstrates Beyond G-Loops
Expanding Cereblon Neosubstrates Beyond G-Loops
Coffee Break
9:30–9:50 AM
Concourse
Lunch
11:15–12:30 PM
Anasazi Ballroom
Poster Session 1
12:00–2:30 PM
Anasazi Ballroom
Symposia Spotlight 1: Late-breaking research presentations selected from abstract submissions
2:30–4:30 PM
Eldorado Ballroom
Stefan A Harry, Massachusetts General Hospital and Harvard University
Systematic Targeting of Protein Complexes with Molecular COUPLrs
Systematic Targeting of Protein Complexes with Molecular COUPLrs
* Charlene M Magtoto, Walter and Eliza Hall Institute of Medical Research
Developing a Pipeline to Validate Potential Therapeutic Targets In Vivo Using Tag Degraders
Developing a Pipeline to Validate Potential Therapeutic Targets In Vivo Using Tag Degraders
William Farnaby, University of Dundee
High-Throughput Multi-Step Degrader Synthesis and Screening Via an Orthogonally Reactive Linker Concept
High-Throughput Multi-Step Degrader Synthesis and Screening Via an Orthogonally Reactive Linker Concept
HONG-YU Li, University of Texas Health San Antonio
A Mechanistic Insight into Cellular Permeability of bRo5 Molecules and Its Applications
A Mechanistic Insight into Cellular Permeability of bRo5 Molecules and Its Applications
Kyubin Hwang, Yonsei University College of Medicine
Discovery of a Potent METTL3 PROTAC With Antitumor Effects Against Acute Myeloid Leukemia and Gastric Cancer
Discovery of a Potent METTL3 PROTAC With Antitumor Effects Against Acute Myeloid Leukemia and Gastric Cancer
Felipe de Sousa e Melo, Amgen
Single Cell Guided Design of Toxicity-Sparing Antibody Antagonists
Single Cell Guided Design of Toxicity-Sparing Antibody Antagonists
Jesus A Izaguirre, Atommap Corporation
Harnessing Biomolecular Motion for Reprogramming of Protein Function: Introducing GlueMap for Molecular Glue Discovery
Harnessing Biomolecular Motion for Reprogramming of Protein Function: Introducing GlueMap for Molecular Glue Discovery
Coffee Available
4:30–5:00 PM
Concourse
New Induced Proximity Approaches
5:00–7:00 PM
Eldorado Ballroom
* Sai Gourisankar, Stanford
Session Chair
Session Chair
Gerald R. Crabtree, Stanford University
Rewiring Cancer Drivers to Activate Programmed Cell Death Pathways
Rewiring Cancer Drivers to Activate Programmed Cell Death Pathways
Xin Zhou, Dana-Farber Cancer Institute
Novel Bifunctional Antibodies for Targeted Membrane Protein Degradation
Novel Bifunctional Antibodies for Targeted Membrane Protein Degradation
Kevan M. Shokat, University of California, San Francisco
Proximity Approaches to Hijack Immune Signaling and Recognition
Proximity Approaches to Hijack Immune Signaling and Recognition
Daniel K Nomura, University of California, Berkeley
Covalent Ligands to Drive Proximity
Covalent Ligands to Drive Proximity
On Own for Dinner
7:00–8:00 PM
Tuesday, February 18, 2025
Breakfast
7:00–8:00 AM
Anasazi Ballroom
Innovation in Induced Proximity Drug Discovery
8:00–11:00 AM
Eldorado Ballroom
William Forrester, Novartis
The Novartis Targeted Protein Degradation Platform
The Novartis Targeted Protein Degradation Platform
* Fleur M. Ferguson, University of California, San Diego
Interrogating the Druggable Proteome with Proximity Pharmacology
Interrogating the Druggable Proteome with Proximity Pharmacology
Philip Chamberlain, Neomorph, Inc.
Expanding the Scope of Glue Degraders
Expanding the Scope of Glue Degraders
Anil Vasudevan, AbbVie, Inc.
The Hunt for Ligands for Tissue-Restricted Ligases
The Hunt for Ligands for Tissue-Restricted Ligases
Christine Jones, Arvinas, Inc.
Short Talk: Development Of Potent, Orally Bioavailable PROTAC LRRK2 Degrader Molecules As Potential Disease Modifying Therapeutics For Neurodegenerative Disorders
Short Talk: Development Of Potent, Orally Bioavailable PROTAC LRRK2 Degrader Molecules As Potential Disease Modifying Therapeutics For Neurodegenerative Disorders
Lindsey Lin, UCSF
Short Talk: MultiMap: Multiscale Interaction Profiling for Cell Surface Neighborhoods
Short Talk: MultiMap: Multiscale Interaction Profiling for Cell Surface Neighborhoods
Coffee Break
9:00–9:20 AM
Concourse
Award Recipient Acknowledgement
9:20–9:25 AM
Eldorado Ballroom
Poster Setup
11:00–1:00 PM
Anasazi Ballroom
On Own for Lunch
11:00–5:00 PM
Poster Viewing
1:00–10:00 PM
Anasazi Ballroom
Women in TPD&IP Networking Social (Sponsored by Neomorph) - OPEN TO ALL!!
1:30–3:00 PM
Anasazi Ballroom
* Fleur M. Ferguson, University of California, San Diego
Session Lead
Session Lead
* Danette L Daniels, Foghorn Therapeutics, Inc
Session lead
Session lead
Career Roundtable
3:00–4:30 PM
Eldorado Ballroom
Francesca Ester Morreale, Francis Crick Institute
Group Leader
Group Leader
Felipe de Sousa e Melo, Amgen
Director - Research Technology and Emerging Modalities
Director - Research Technology and Emerging Modalities
Georg Petzold, Monte Rosa Therapeutics
Senior Scientist II, Discovery Technologies
Senior Scientist II, Discovery Technologies
Nicola J. Allen, The Salk Institute for Biological Studies
Associate Professor
Associate Professor
Coffee Available
4:30–5:00 PM
Concourse
Clinical Progress in Proximity Technologies
5:00–7:00 PM
Eldorado Ballroom
* Michelle R. Arkin, University of California, San Francisco
Session Chair
Session Chair
Danette L Daniels, Foghorn Therapeutics, Inc
Clinical Progress in Degrading Epigenetic Disease Drivers
Clinical Progress in Degrading Epigenetic Disease Drivers
Vivek K. Arora, Bristol Myers Squibb
Clinical Advances in Cereblon-based Heterobifunctional and Glue Degraders
Clinical Advances in Cereblon-based Heterobifunctional and Glue Degraders
Juliet Williams, Kymera Therapeutics
Preclinical to Clinical Translation: Building an Immunology Pipeline of Heterobifunctional Degraders
Preclinical to Clinical Translation: Building an Immunology Pipeline of Heterobifunctional Degraders
Lynda Groocock, Bristol Myers Squibb
Short Talk: BCL6 Ligand Directed Degrader (LDD) BMS-986458 is a First-In-Class, Highly Selective, Efficacious and Well Tolerated Potential Treatment for B-cell Non-Hodgkin’s Lymphoma
Short Talk: BCL6 Ligand Directed Degrader (LDD) BMS-986458 is a First-In-Class, Highly Selective, Efficacious and Well Tolerated Potential Treatment for B-cell Non-Hodgkin’s Lymphoma
Lucilia Pereira Mouries, Health & Environmental Sciences Institute (HESI)
Short Talk: Collaborative Approaches to Advance Integrated Safety Assessment of Targeted Protein Degraders
Short Talk: Collaborative Approaches to Advance Integrated Safety Assessment of Targeted Protein Degraders
Social Hour with Lite Bites
7:00–8:00 PM
Anasazi Ballroom
Poster Session 2
7:30–10:00 PM
Anasazi Ballroom
Wednesday, February 19, 2025
Breakfast
7:00–8:00 AM
Anasazi Ballroom
Beyond Degredation: New Applications of Induced Proximity
8:00–11:00 AM
Eldorado Ballroom
* Lauren V Albrecht, University of California Irvine
Session Chair
Session Chair
Steven Banik, Stanford University
Targeted Protein Relocalization
Targeted Protein Relocalization
Amit Choudhary, Harvard Medical School
A Scalable Design for Proximity-Inducing Molecules
A Scalable Design for Proximity-Inducing Molecules
Michelle R. Arkin, University of California, San Francisco
Hacking Native Protein-Protein Interaction Networks with Molecular Glues
Hacking Native Protein-Protein Interaction Networks with Molecular Glues
Francesca Ester Morreale, Francis Crick Institute
Enabling Targeted Protein Degradation in Bacteria
Enabling Targeted Protein Degradation in Bacteria
Lawrence Hamann, Interdict Bio, Inc.
Short Talk: Sequence Selective Translation Inhibition as a Novel, Proximity-Based Cancer Therapeutic Modality
Short Talk: Sequence Selective Translation Inhibition as a Novel, Proximity-Based Cancer Therapeutic Modality
William J Gibson, Dana Farber Cancer Institute
Short Talk: p53 Protein Abundance is a Therapeutic Window Across TP53 Mutant Cancers and is Targetable With Proximity Inducing Small Molecules
Short Talk: p53 Protein Abundance is a Therapeutic Window Across TP53 Mutant Cancers and is Targetable With Proximity Inducing Small Molecules
Coffee Break
9:00–9:20 AM
Concourse
On Own for Lunch
11:00–2:30 PM
Symposia Spotlight 2: Late-breaking research presentations selected from abstract submissions
3:00–4:30 PM
Eldorado Ballroom
Alexandra Lantermann, Photys Therapeutics
P53-Y220C-BET-Bifunctionals Drive p53-Y220C-Mutant Cancer Cells into Apoptosis
P53-Y220C-BET-Bifunctionals Drive p53-Y220C-Mutant Cancer Cells into Apoptosis
Markella Konstantinidou, University of California, San Francisco
Rational Approaches for The Systematic Identification of Covalent Molecular Glues
Rational Approaches for The Systematic Identification of Covalent Molecular Glues
Jean-Francois Brazeau, Plexium
Ultra-High-Throughput Miniaturized Cell-Based Assays to Discover CDK2 Molecular Glue Degraders
Ultra-High-Throughput Miniaturized Cell-Based Assays to Discover CDK2 Molecular Glue Degraders
Dhanusha Nalawansha, Amgen
LYMTACs: Chimeric Small Molecules Repurpose Lysosomal Membrane Proteins for Target Protein Relocalization and Degradation
LYMTACs: Chimeric Small Molecules Repurpose Lysosomal Membrane Proteins for Target Protein Relocalization and Degradation
Hadir Marei, Genentech, Roche
Target Clearance: Targeted Protein Degradation At The Cell Surface
Target Clearance: Targeted Protein Degradation At The Cell Surface
* George M Burslem, University of Pennsylvania
Pooled Endogenous Protein Tagging and Recruitment for Scalable Discovery of Effectors for Induced Proximity Therapeutics
Pooled Endogenous Protein Tagging and Recruitment for Scalable Discovery of Effectors for Induced Proximity Therapeutics
Coffee Available
4:30–5:00 PM
Concourse
Hijacking New Components of the Degradation Machinery
5:00–6:45 PM
Eldorado Ballroom
* Danette L Daniels, Foghorn Therapeutics, Inc
Session Chair
Session Chair
Stefan Knapp, SGC Frankfurt
E3-Ligases and updates from the SGC
E3-Ligases and updates from the SGC
Natalie Scholes, CeMM
When Inhibitors Act as Degraders: Supercharging Protein Turnover via Endogenous Degradation Routes
When Inhibitors Act as Degraders: Supercharging Protein Turnover via Endogenous Degradation Routes
Henry M. Colecraft, Columbia University
Hacking the Polyubiquitin Code to Understand and Manipulate Ion Channel Functional Expression
Hacking the Polyubiquitin Code to Understand and Manipulate Ion Channel Functional Expression
Laurence J Seabrook, University of California, Irvine
Short Talk: Methylarginine Targeting Chimeras for Lysosomal Degradation of Intracellular Proteins
Short Talk: Methylarginine Targeting Chimeras for Lysosomal Degradation of Intracellular Proteins
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
6:45–7:00 PM
Eldorado Ballroom
Social Hour with Lite Bites
7:00–8:00 PM
Anasazi Ballroom
Entertainment
8:00–9:00 PM
Eldorado Ballroom
Cash Bar
8:00–9:00 PM
Anasazi Ballroom
Thursday, February 20, 2025
Departure
12:00–11:59 PM
Subscribe for Updates